Table 1 Demographic data and clinical characteristics of patients with hepatocellular carcinoma
Non-cirrhosis n = 200 (%) | Cirrhosis n = 2328 (%) | P values | |
|---|---|---|---|
Age(mean ± SD) | 53.36 ± 11.94 | 56.96 ± 10.34 | < 0.0001 |
Gender (male) | 164 (82.0) | 1793 (77.0) | 0.106 |
Family history of HCC | 0.005 | ||
Yes | 14 (7.0) | 74 (3.2) | |
No | 186 (93.0) | 2254 (96.8) | |
Smoking | 0.131 | ||
Smoker | 91 (45.5) | 932 (40.0) | |
Non-smoker | 109 (54.5) | 1396 (60.0) | |
Alcohol | 0.759 | ||
alcohol | 79 (39.5) | 894 (38.4) | |
No alcohol | 121 (60.5) | 1434 (61.6) | |
Diabetes | < 0.0001 | ||
Yes | 21 (10.5) | 506 (21.7) | |
No | 179 (89.5) | 1822 (78.3) | |
Hypertension | 0.81 | ||
Yes | 50 (25) | 600 (25.8) | |
No | 150 (75) | 1728 (74.2) | |
Hyperlipidemia | 0.002 | ||
Yes | 25 (12.5) | 154 (6.6) | |
No | 175 (87.5) | 2174 (93.4) | |
Coronary artery disease | 0.918 | ||
Yes | 5 (2.5) | 61 (2.6) | |
No | 195 (97.5) | 2267 (97.4) | |
Etiology | 0.003 | ||
HBV | 153 (76.5) | 1823 (78.3) | |
HCV | 23 (11.5) | 177 (7.6) | |
Alcohol abuse | 10 (5.0) | 248 (10.7) | |
NAFLD | 4 (2.0) | 25 (1.1) | |
idopathic | 10 (5.0) | 55 (2.4) | |
HBeAg at baseline | 0.005 | ||
Negative | 98 (54.1) | 1289 (60.6) | |
Positive | 45 (24.9) | 572 (26.9) | |
Missing data | 38 (21.0) | 265 (12.5) | |
HBV-DNA at baseline | 0.024 | ||
Low(< 500 IU/ml) | 71 (41.3) | 791 (39.8) | |
High(> 500 IU/ml) | 63 (36.6) | 894 (45.0) | |
Missing data | 38 (22.1) | 301 (15.2) | |
Antiviral therapy | 0.972 | ||
Yes | 146 (79.3) | 1686 (79.0) | |
No | 29 (15.8) | 348 (16.3) | |
Missing data | 9 (4.9) | 99 (4.6) | |
Tumor diameter (cm) | 3.5 (2.3, 6.2) | 3.1 (2.0, 5.7) | 0.213 |
Tumor multiplicity | < 0.0001 | ||
solitary | 136 (72) | 1259 (55.1) | |
multiple | 53 (28) | 1024 (44.9) | |
PVTT at baseline | < 0.0001 | ||
Yes | 14 (7.0) | 479 (20.6) | |
No | 186 (93.0) | 1849 (79.4) | |
AFP (ng/ml) | 0.754 | ||
AFP < 400 | 148 (74.0) | 1746 (74.9) | |
AFP ≥ 400 | 52 (26.0) | 634 (25.1) | |
BCLC staging | < 0.0001 | ||
0-A | 106 (53.0) | 835 (37.3) | |
B | 73 (36.5) | 734 (31.9) | |
C | 18 (9.0) | 433 (17.8) | |
D | 3 (1.5) | 326 (13.0) | |
Treatment for HCC | 0.002 | ||
Resection | 30 (15.0) | 185 (7.9) | |
Minimally invasive | 132 (66.0) | 1578 (67.8) | |
Palliative | 38 (19.0) | 565 (24.3) | |
MELD scores | 3.4 (1.29,5.30) | 5.39 (2.36,8.48) | < 0.0001 |
Leukocyte counts (109/L) | 4.43 (5.71,7.25) | 3.05 (4.32,5.90) | < 0.0001 |
NLR | 2.19 (1.55,3.68) | 2.44 (1.62,3.97) | 0.019 |
Platelets (109/L) | 151.8 (112.5197.08) | 87.25 (57.23,136.5) | < 0.0001 |
ALT (U/L) | 32.1 (22.72,56.7) | 33.2 (22.3,54.2) | 0.9 |
AST (U/L) | 31.15 (23.8,54.03) | 42.4 (28.83,72.13) | < 0.0001 |
Totall Bilirubin (umol/L) | 13.4 (9.7,16.98) | 19.85 (13.2,32.48) | < 0.0001 |
γ-GGT (U/L) | 44.9 (25.9,94.33) | 59.35 (33.22,123.8) | < 0.0001 |
Albumin (g/L) | 40.09 ± 4.80 | 35.014 ± 6.34 | < 0.0001 |
Triglyceride (mmol/L) | 1.009 ± 0.49 | 0.87 ± 0.45 | < 0.0001 |
Prothrombin activity (%) | 88.77 ± 14.51 | 75.06 ± 18.00 | < 0.0001 |
Child Staging | < 0.0001 | ||
A | 177 (88.5) | 1125 (48.3) | |
B | 20 (10.0) | 877 (37.7) | |
C | 3 (1.5) | 326 (14.0) | |